CRGX250117P15000
- 0.50
- 0.000.00%
CARGO Therapeutics Newsroom
Truist Financial Maintains CARGO Therapeutics(CRGX.US) With Buy Rating
Piper Sandler Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $34
William Blair Maintains CARGO Therapeutics(CRGX.US) With Buy Rating
William Blair Initiates CARGO Therapeutics(CRGX.US) With Buy Rating
H.C. Wainwright Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $33
Promising Outlook for Cargo Therapeutics: Buy Rating Backed by Strong Financials and Clinical Developments
Truist Financial Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $32
Chardan Capital Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $28
Cargo Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on Cargo Therapeutics, Maintains $28 Price Target
Piper Sandler Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $34
Piper Sandler Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $34
J.P. Morgan Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $30
Firi-cel's Promising Outlook and Undervalued Potential Drive Buy Rating for CARGO Therapeutics
Piper Sandler Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $34
Piper Sandler Reaffirms Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)
Truist Financial Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $32
CARGO Therapeutics Price Target Maintained With a $33.00/Share by HC Wainwright & Co.
Piper Sandler Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Cuts Target Price to $34
Cargo Therapeutics Analyst Ratings